(NASDAQ: XFOR) X4 Pharmaceuticals's forecast annual revenue growth rate of 47.69% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 86.2%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.83%.
X4 Pharmaceuticals's revenue in 2025 is $31,364,000.On average, 4 Wall Street analysts forecast XFOR's revenue for 2025 to be $204,988,949, with the lowest XFOR revenue forecast at $199,593,893, and the highest XFOR revenue forecast at $212,444,776. On average, 4 Wall Street analysts forecast XFOR's revenue for 2026 to be $122,500,173, with the lowest XFOR revenue forecast at $65,412,152, and the highest XFOR revenue forecast at $197,973,061.
In 2027, XFOR is forecast to generate $730,242,739 in revenue, with the lowest revenue forecast at $123,472,672 and the highest revenue forecast at $1,833,276,856.